No Data
Buy Rating Affirmed for Scynexis on Robust Financials and Promising Antifungal Pipeline
Analysts' Top Healthcare Picks: Cormedix (CRMD), SCYNEXIS (SCYX)
Buy Recommendation: Scynexis's Ibrexafungerp Promises Market Breakthrough and Financial Growth
SCYNEXIS Q1 2024 GAAP EPS $0.01 Beats $(0.20) Estimate, Sales $1.400M Beat $303.000K Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.20) by 105 percent. The company reported quarterly sales of $1.400 million which
Earnings Flash (SCYX) SCYNEXIS Reports Q1 Revenue $1.4M
04:51 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (SCYX) SCYNEXIS Reports Q1 Revenue $1.4M
Scynexis Projects a Cash Runway of More Than Two Years >SCYX
Scynexis Projects a Cash Runway of More Than Two Years >SCYX